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Abstract
Background: Among the salivary gland carcinomas, carcinoma in pleomorphic adenoma has been
regarded as a representative carcinoma type which arises secondarily in the background of a pre-
existent benign pleomorphic adenoma. It is still poorly understood how and which benign
pleomorphic adenoma cells transform into its malignant form, carcinoma ex pleomorphic adenoma.
Methods: We have established five cell systems from a benign pleomorphic adenoma of the
parotid gland of a 61-year-old woman. They were characterized by immunofluorescence, classical
cytogenetics, p53 gene mutational analysis, fluorescence in-situ hybridization, and histopathological
and immunohistochemical examinations of their xenografts, to demonstrate their potency of
secondary transformation.
Results: We established and characterized five cell systems (designated as SM-AP1 to SM-AP5)
from a benign pleomorphic adenoma of the parotid gland. SM-AP1 to SM-AP3 showed polygonal
cell shapes while SM-AP4 and SM-AP5 were spindle-shaped. SM-AP1-3 cells were immunopositive
for keratin only, indicating their duct-epithelial or squamous cell differentiation, while SM-AP4/5
cells were positive for both keratin and S-100 protein, indicating their myoepithelial cell
differentiation. Chromosome analyses showed numeral abnormalities such as 5n ploidies and
various kinds of structural abnormalities, such as deletions, translocations, derivatives and
isodicentric chromosomes. Among them, der(9)t(9;13)(p13.3;q12.3) was shared by all five of the
cell systems. In addition, they all had a common deletion of the last base G of codon 249 (AGG to
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AG_) of the p53 gene, which resulted in generation of its nonsense gene product. Transplanted
cells in nude mice formed subcutaneous tumors, which had histological features of squamous cell
carcinoma with apparent keratinizing tendencies. In addition, they had ductal arrangements or
plasmacytoid appearances of tumor cells and myxoid or hyaline stromata, indicating some
characteristics of pleomorphic adenoma.
Conclusion: This study demonstrates in vitro that certain cell types from pleomorphic adenoma
are able to clone and survive over a long term and develop subcutaneous tumors in nude mice. The
histological features of squamous cell carcinoma from the transplanted cell systems in nude mice
might suggest a secondary onset of malignancy from a pre-existing benign adenoma.
Background
Among the salivary gland carcinomas, carcinoma ex pleo-
morphic adenoma has been regarded as only one carci-
noma type, which is considered to arise in the background
of a pre-existent benign adenoma. The frequencies of the
secondary onset of carcinoma have been recorded to be
6.2% to 8.8% among pleomorphic adenomas, although
cellular mechanisms for how carcinoma cells develop in
pleomorphic adenomas are poorly understood [1,2]. In
our previous study, we proposed a concept of focal carci-
nomas in pleomorphic adenoma which is an advanced
stage of accumulated atypical cells with P53 over-expres-
sions as an initial stage or a latent form of apparent carci-
nomas secondarily arising in pleomorphic adenoma [3].
Although pathologists in their daily services of surgical
pathology had recognized such singular atypical cells in
pleomorphic adenomas, these atypical cells were not
always regarded as evidence or the source for malignant
transformation [4-6].
Pleomorphic adenomas have been often subjected to
cytogenetic and molecular analyses. Among those studies,
the PLAG1 (pleomorphic adenoma-related gene), which
is located in 8q12, has been investigated most extensively.
PLAG1 is consistently rearranged in pleomorphic ade-
noma by translocations t(3;8)(p21;q12) [7,8] and
t(5;8)(p13;q12) [9]. These translocations have been
regarded as one of the major responsible genetic events
for the tumorigenesis of pleomorphic adenoma. As
another important cancer-related gene, the p53 gene has
been most extensively investigated in surgical samples of
both benign pleomorphic adenoma, focal carcinoma in
pleomorphic adenoma [3] and carcinoma ex pleomor-
phic adenoma [10-18], and mutations in the p53 gene
have been considered to be responsible for the malignant
transformation of pleomorphic adenoma [10-12].
There have been three trials in the literature to establish
cell lines/systems from pleomorphic adenomas [19-21]
and two from carcinoma ex pleomorphic adenomas
[13,22], in addition to those from mere primary cultures
[7-9,23-27]. Kondo et al. [19] established an epithelial cell
line named Nagoya-78 from a benign pleomorphic ade-
noma of the lip and showed that the cells contained 62–
65 chromosomes with plenty of abnormalities. They also
transplanted the cells in hamsters, whose histological
phenotypes were malignant myoepitheliomas, to gener-
ate tumors within a few weeks. Jaeger et al. [20] also estab-
lished a cell line named AP2 from a benign pleomorphic
adenoma of the parotid gland, which showed myoepithe-
lial-like characteristics in a three dimensional culture.
Another cell line from a palatal pleomorphic adenoma
was HPA by Shirasuna et al. [21]. This cell line was
revealed ultrastructurally to show a myoepithelial differ-
entiation. These reports described malignant or trans-
formed natures of the cells, while no definite histological
characteristics of squamous cell carcinoma were demon-
strated. Unfortunately, no further investigations for these
cell lines after the initial reports have been conducted, nor
has any attention been paid to the gene mutational events
in the salivary gland adenoma-carcinoma sequence.
It is thus necessary to analyze the pathogenetic mode of
the secondary onset of carcinomas in benign pleomorphic
adenomas further in vitro, because most of the previous
investigations have been limited to only surgical speci-
mens and primary cultures. In the present study, our aim
was to clone cell systems from a pleomorphic adenoma to
characterize its transformed cells in various aspects. Since
we were successful in establishing five cell systems after a
long-period of primary culture from a benign pleomor-
phic adenoma, we analyzed these cells for cellular differ-
entiation, chromosomal abnormality, p53 gene mutation,
and histology of xenografted tumors in nude mice.
Methods
Tumor sample
A fresh tissue sample was obtained from a parotid gland
tumor of a 61-year-old woman. The tumor, measuring 23
× 20 × 15 mm in size, was surgically removed with tumor-
free margins. The surgical material was fixed in 10% for-
malin, cut into about 3–5 mm thick slices using whole-
organ sectioning, and embedded in paraffin. Sections 5
m thick were cut from the cut surfaces of the tumor spec-
imens and stained with hematoxylin and eosin (HE).
Macroscopically, the tumor was circumscribed with aBMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
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fibrous capsule, and was grayish white in color, solid, firm
and mucinous in its cut surface. There were no signs of
local recurrence or metastasis during her three-year post-
operative course. The experimental protocol for isolation
and analyses of tumor cells was reviewed and approved by
the Niigata University Graduate School of Medical and
Dental Sciences Ethical Board. Prior to obtaining the tis-
sue samples, our purpose and plan of the experiment were
explained to the patient followed by her consent.
Primary culture and cloning
A tissue slice obtained from the central and maximum cut
surface of the surgical material was minced into small
pieces. The tissue pieces were treated with 0.1% (v/w) col-
lagenase (F. Hoffmann-La Roche Ltd., Basel, Switzerland)
in Dulbecco's minimal essential medium (DMEM, Gibco,
Invitrogen. Co., Carlsbad, CA, USA) containing 10% fetal
calf serum (Gibco), 50 IU/ml penicillin and 50 g/ml
streptomycin (Gibco) in a 2 ml tube for 8 hrs at 37°C.
Pass-through fractions from a nylon mesh filter were
washed and plated in 2 ml of DMEM in 35 mm dishes and
incubated at 37°C in humidified 5% carbon dioxide/95%
air atmosphere. After two weeks, culture media were
replaced with fresh ones and thereafter changed every 7
days. After one month, the cells, which had grown to con-
fluence, were split into 25 cm2 flasks. When aggregates of
polygonal and bizarre epithelioid cells appeared in the
background of spindle-shaped cells in the fourth passage,
the cells were split and thereafter passaged every week.
After four passages, the cells were served for cloning. The
cells prepared as above were plated in 96-well microplates
using a conventional method of dilution [28]. Wells with
a single cell were observed every 24 hrs by microscope.
The culture media were changed every 2 days. After the
cells reached subconfluency in the wells, they were trans-
ferred into 24 well plates and maintained for up to 1
month until they reached subconfluent conditions, and
then the cells were moved to 25 cm2 flasks.
Immunohistochemistry
All of the established cell systems were used for immun-
ofluorescence studies. The cells were seeded at a cell con-
centration of 1.2 × 104 onto each well of chamber slides
(Lab-Tek II, 4-well type, Nalge Nunc International, Naper-
ville, IL, USA) and cultivated for 6 days. At day 6 after plat-
ing, the chamber slides were fixed and served for
immunofluorescence experiments [29]. The primary anti-
bodies consisted of rabbit polyclonal antibodies against
human keratin (wide spectrum, Dako, Glostrup, Den-
mark, diluted at 1:25), and human S-100 protein (Dako,
1:100) and mouse monoclonal antibodies against human
cytokeratin (CK) 14 (clone CKB1, IgM, 1: 100, Sigma
Chemical Co., St Louis, MO, USA), calpoinin (CALP1,
IgG1, 1:50, Dako), and P53 protein (IgG2a, specific to the
transcription domain in the NH2-terminal region, clone
Bp53-11, Progen Bioteknik GmbH, Heidelberg, Ger-
many). The secondary antibodies were rhodamine-conju-
gated goat anti-rabbit or mouse IgGs or IgM (ICN
Pharmaceuticals, Aurora, OH, USA, 1:50). For control
studies, purified non-immune rabbit IgG or mouse IgG2a
(Dako) were used instead of the specific primary antibod-
ies. Xenografts of pleomorphic adenoma cell systems in
nude mice were also examined immunohistochemically
for perlecan, a basement membrane type heparan sulfate
proteoglycan, and fibronectin by using rabbit polyclonal
antibodies (diluted at 50 g/ml, respectively) [29] and the
rabbit Envision+/HRP system (Dako). For control studies
on the antibodies, the primary antibodies were replaced
with preimmune rabbit IgG.
DNA Extraction
Cellular DNAs were extracted from cells in primary cul-
ture and from all of the five established cell systems by
using a TRIzol system (Invitrogen). The cells were culti-
vated for 7 days up to their subconfluency in 25 cm2
flasks, and 1 ml of TRIzol reagent was added to each flask.
Total RNAs were then extracted from the cell lysate accord-
ing to the manufacturer's instructions. After complete
removal of the aqueous RNA phase, DNA was isolated
from the interphase and phenol-phase. Following precip-
itation with 0.1 M sodium citrate in 10% ethanol, the pre-
cipitants were washed with 70% ethanol, and the pellets
were air-dried briefly. The DNA samples dissolved in
autoclaved water were stored at -20°C.
Polymerase chain reaction (PCR)
Exons 5-7 of the p53  gene were PCR amplified for
sequencing to examine mutational events in cells in pri-
mary culture and all of the cloned cell systems. For exon
5, a set of primers (forward, 5'-TTCAA CTCTG TCTCC
TTCCT-3'; reverse, 5'-GACCT CTCTG CTGTC CCGAC-3')
was used to generate a 323 bp fragment. For exon 6, a set
of primers (forward, 5'-GCCTC TGATT CCTCA CTGAT-3';
reverse, 5'-AGAGA CCCTC CTCCC CAATT-3') was used
for a 223 bp fragment. For exon 7, a set of primers (for-
ward, 5'-CTTGC CACAG GTCTC CCCAA-3'; reverse, 5'-
CGGTG AACGG TGGGA CGTGT-3') was used for a 453
bp fragment. After first denaturation at 94°C for 4 min,
the experimental protocol for 35-cycle PCR was per-
formed as follows: denaturation at 94°C for 1 min,
annealing at 60°C for 1 min, extension at 72°C for 1 min,
and termination with a final extension at 72°C for 7 min.
Their sequence primer sets were from the nested primers
used in the PCR experiments but with Texas red labeling
at their 5'ends.
Direct sequencing of PCR products
All the PCR products for exons 5, 6 and 7 of the p53 gene
were subjected to direct sequencing by using Thermo
Sequenase Primer Core Cycle Sequencing kits with 7-BMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
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deaza-dGTP (GE Healthcare Ltd./Amersham, Bucking-
hamshire, UK). One reaction mixture contained 3 l of
pre-mixes (appropriate nucleotides/reaction buffer/
Thermo Sequenase DNA polymerase), 1 l of the tem-
plate PCR products purified with GFX PCR DNA and Gel
Band Purification kit (Amersham), and 2 l (2 pM) of
Texas red-labeled primers. After denaturation at 95°C for
2 min, the reaction mixture was placed on a thermal cycler
for 25 cycles of denaturation at 95°C for 30 sec and
annealing/extension at 60°C for 30 sec. The reaction
products were dissolved in 3 l loading buffer and con-
centrated with a vacuum desiccator. Then, 3 l of samples
for each lane were loaded on a gel [7% Long Ranger (Bio-
whittaker Molecular Applications, Rockland, ME, USA)/
6.1 M urea/1.2 × TBE buffer (0.445 M Tris-HCl, 0.445 M
boric acid, 0.01 M EDTA)]. The electrophoresis was per-
formed in a fluorescent DNA sequencer (SQ-5500-S,
Hitachi Ltd., Tokyo, Japan) and the sequencing data were
analyzed by using the SQ-5500 analysis software ver. 3.03
(Hitachi).
Chromosomal analysis
Primary culture cells in the fourth passages and all of the
established cell systems in their subconfluent conditions
were arrested for 3.5 hrs with 0.06 g/ml colcemid in
DMEM. They were washed two times with PBS and then
removed with 0.05% trypsin at 37°C for 5 min. The cells
were recovered from culture dishes with DMEM, sus-
pended in 0.075 M KCl at 37°C for 30 min for hypotonic
treatment, and then fixed in 1:3 acetic acid/methanol. The
cell suspension was dropped onto glass slides to spread
chromosomes from cells in the metaphase at room tem-
perature under 50–55% ambient humidity. Slides were
stained with 6% Giemsa solution in 0.067 M phosphate
buffer (pH 6.8) for visualization of chromosomes. Met-
aphase spreads from 20 to 50 cells of the primary culture
and each cell system were counted for chromosome num-
bers. Other slides were treated with 0.005% trypsin at 2°C
for 8 min. They were washed and then stained with
Giemsa solution for visualization of Giemsa (G)-banding.
Ten to twenty cells each were analyzed for G-banded kary-
otypes in all of the cell systems. For control studies,
peripheral blood lymphocytes from the patient were cul-
tured in RPMI 1640 (Gibco) containing 10% fetal calf
serum (Gibco), 50 IU/ml penicillin and 50 g/ml strepto-
mycin (Gibco) for 3 days, and then analyzed for chromo-
some numbers and G-banded karyotypes in the same way
as described above.
Fluorescence in-situ hybridization (FISH) analysis of 
human bacterial artificial chromosome (BAC) clones
The genomic clones encoding the break point regions
around t(9;13)(p13;q12) were isolated from the BAC
library [30] by the PCR screening method with primer sets
flanking the regions of the two chromosomes by using the
GenBank database http://www.ncbi.nlm.nih.gov/ as
shown in Table 1. About 10 l of the DIG-labeled BAC
DNA was mixed in 2 l of 10 mg/ml salmon sperm DNA
(Roche), 2 l of 10 mg/ml E. coli tRNA (Roche), 4 l of 4
M CH3COONH4, and 50 l of 100% ethanol. After stor-
age for 1 hr at -80°C, the mixture was melted and centri-
fuged in 8 l of the hybridization mixture consisting of
50% formamide, 10% dextran sulfate, 2 × SSC solution
for each slide. After 2 l of 10.5 mg/ml human placenta
DNA (Sigma) was added, the mixtures were denatured for
10 min at 75°C, cooled down, and supplemented with 1
l BSA. The mixture was pre-annealed for 30 min at 37°C
before applying it to the slides. Slide-bound chromo-
somal DNA was denatured in a solution of 70% forma-
mide in 2 × SSC for 6 min at 75°C on preheated slides for
2 hrs at 60°C and dehydrated in a 4°C ethanol series
(70% and 100% ethanol for 5 min each). Ten microliters
Table 1: BAC correlated with human data in the database and primer sequences for each BAC clone.
Chromosomal location in human Primer
BAC clones Accession number Forward sequence Reverse sequence PCR-Product (bp)
1537E12 9p13.2 AL161445 TGCTTCTTGGAAATCAAGTCAA
AGGGTTAT
CTGAATCTGGCACTTGGATTGT
CTCCATTC
150
1405F1 9p13.1 AL138834 TCAATGTCCCTTTGACCATTTC
CAAATTCA
TTGAAGTCCACAGCTGCTGTGC
CTCTGAAA
202
1529G11 9p12 AL161448 CCCTAAGAGGACCTGCAATTCT
TCCTTCAG
GTTTTGTGGACCTTGAAGTGCT
ATATGGAA
190
1011G7 13q12.11 AL161772 ACTGGAGAGAATTTACTTTTAC
TTATGGTA
TTGAGACTCACAGCCTGAAGG
GATAAACAC
250
2037C1 13q12.12 AL356287 CATTTCTTTGCCCTATAGACCT
GATTGAAA
CTGTGCTCCCTTCATATAGCTT
GTCTTCCTA
173
1325C2 13q12.2 AL591024 GCAAAATCCAGGGGTAGAGCT
GAGTTGTGA
CTGAGATGGATTCTGTATTTGC
CTATTTAC
140
1213F4 13q13.1 AL136160 CATCAAATGCCGTTTGAAGATA
TGAAGATG
TTTGGGAGCATCTTGACAGAAT
CCCTTTGA
180BMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
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of the hybridization mixture were applied to each slide,
and the slides were sealed with cover glasses. After over-
night incubation at 37°C, the cover glasses were removed
and the slides were washed once in 50% formamide/2 ×
SSC for 20 min at 37°C and twice in 2 × SSC for 10 min
at 37°C, and then in TNT solution (0.1 M Tris-HCl/0.15
M NaCl/0.05% Tween 20) for 5 min at room temperature.
The slides were further incubated with 100 l of TNB solu-
tion (0.1 M Tris-HCl/0.15 M NaCl/0.5% blocking solu-
tion (Dainippon Pharmaceutical Co. Ltd., Osaka, Japan)
to block non-specific reactions. The DIG-labeled probes
were reacted with the anti-DIG mouse monoclonal anti-
body (Roche, 50 l of 1 g/ml IgG/4 × SSC) for 30 min at
room temperature, rinsed three times in TNT solution for
5 min, and then treated with the secondary antibody (40
l of 10 g/ml Alexa flour 488-conjugated goat anti-
mouse IgG (Molecular Probes, Inc., Eugene, OR, USA)).
Finally, the FISH slides were counterstained with 50 g/
ml propidium iodide (PI, Vector Laboratories, Burlin-
game, CA, USA) for 30 min at room temperature. FISH
images were obtained by an Olympus confocal laser scan-
ning microscope Fluoroview 1000 (Olympus Co., Tokyo,
Japan).
Xenografts in nude mice
To determine in vivo tumorigenicities of the cloned cell
systems, SM-AP cells were transplanted in nude mice.
Cells in their 9th to 13th in vitro passages at a concentra-
tion of 2 × 106 in 0.3 ml culture media were injected into
the lateral back wall of female BALB/c (nu/nu) mice at 4
weeks of age (2 mice each per cell system). The animals
were housed in clean boxes in a sanitary and ventilated
animal room and maintained under constant conditions
(at 22°C and in a 12-hr light/dark cycle) with free access
to sterilized solid food and autoclaved water. When
tumors reached sizes of around 10–15 mm in diameter,
they were surgically removed with the animals under
ether anesthesia. The excised tumor tissues were fixed in
10% formalin for 24 hrs at 4°C and embedded in paraf-
fin. Serial sections cut at 5 m from the paraffin blocks
were stained with hematoxylin and eosin, Masson's tri-
chrome and immunoperoxidase for perlecan, fibronectin,
keratin, S-100 and P53, and then examined histologically.
The experimental research by using animals was reviewed
and approved by the Niigata University Graduate School
of Medical and Dental Sciences Ethical Board.
Results
Tissue sample histology
The surgical specimen of the parotid gland tumor showed
a typical histology of pleomorphic adenoma with a defi-
nite capsule (Figure 1A). The tumor contained both
myxoid and hyaline areas with varied cellularity but poor
vascularity. There were neither apparent foci of carcinoma
cells nor pleomorphic adenoma cells with apparent atyp-
ical features (Figure 1B).
Establishment of pleomorphic adenoma cell systems
For the first to third cell passages of the primary culture, it
took about 2 months for each of the cells to form a con-
fluent monolayer in a 25 cm2 flask ready for splitting.
During the period up to the third passage, cells were
almost spindle-shaped in isolated colonies but did not
show any fascicular modes of packing as seen in fibrob-
lasts (Figure 1C). At the fourth passage, clusters of polyg-
onal cells with ground glass-like cytoplasm started to
appear among the spindle-shaped cells (Figure 1D), and
the cells reached confluence in 7 days. After four addi-
tional passages, during which polygonal cells became
enhanced in their atypical features in size and shape of
their nuclei and such bizarre cells increased in number in
most of the colonies, these cells were served for cloning.
From serial dilutions in 96-well microplates, single cells
were isolated in individual wells and grew to confluence
within one month after plating. They were transferred into
24-well plates and then to a 25 cm2 flask. These cloning
procedures were repeated twice, and finally, 5 clones were
successfully grown from the primary culture. They were
designated as SM-AP1 to SM-AP5. After the cloning proce-
dure, the five cloned cell systems were maintained by pas-
sages every 7 days. Their doubling times were
approximately 31 hrs irrespective of the five cell systems.
They were classified into two groups according to their cell
shapes: one was polygonal with squamous epithelial char-
acteristics, which was shared by SM-AP1 (Figure 1E), SM-
AP2, and SM-AP3, and the other was short spindle
shaped, which was characteristic of SM-AP4 and SM-AP5
(Figure 1F).
Immunofluorescence of clones SM-AP cell systems
Clones SM-AP1 to SM-AP5 were stained positive for kera-
tin, a duct-epithelial marker (Figures 2A–2D). SM-AP1,
SM-AP2, and SM-AP3 cells were not positive for S-100
protein, a myoepithelial marker (Figures 2C), while SM-
AP4 and SM-AP5 cells were strongly positive (Figures 2D)
mainly in their nuclei. In addition to S-100 protein, SM-
AP4 and SM-AP5 were positive for such myoepithelial
markers as CK14 and calponin. All primary cultured cells
and five cell systems showed immunopositivities for per-
lecan but none for P53 protein (not shown).
Chromosome analysis
Chromosome numbers of the five cell systems varied
between 64 and 123, which were within tetraploid or pen-
taploid ranges, with a modal chromosome number of 108
(Figure 3A-a–e). Chromosome numbers of primary cul-
tured cells varied between 107 and 122 with a modal
chromosome number of 113 (Figure 3A-f). The G-banded
karyotyping revealed a stemline karyotype ofBMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
Page 6 of 17
(page number not for citation purposes)
Figure 1 (see legend on next page)BMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
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Histopathology of pleomorphic adenoma from which cells were isolated (A, HE stain, × 40; B, HE stain, × 200) and phase-con- trast microscopy of pleomorphic adenoma cells (C, primary culture, ×100; D, colony with bizarre cells, ×135; E, established cell  system SM-AP3, × 150; F, SM-AP5, × 150) Figure 1 (see previous page)
Histopathology of pleomorphic adenoma from which cells were isolated (A, HE stain, × 40; B, HE stain, × 200) 
and phase-contrast microscopy of pleomorphic adenoma cells (C, primary culture, ×100; D, colony with 
bizarre cells, ×135; E, established cell system SM-AP3, × 150; F, SM-AP5, × 150). The surgical specimen showed typ-
ical features of benign pleomorphic adenoma (A), containing only a small number of atypical tumor cells (B). Cells in the pri-
mary culture were mainly spindle in shape mixed with fewer amounts of polygonal cells (C). In the fourth passage, aggregates 
of polygonal and bizarre epithelioid cells appeared in the background of spindle-shaped cells (D). From the following passage, 
five clones were successfully grown and isolated. They were classified into two groups according to their cell shapes. One was 
a polygonal shape represented by SM-AP3 (E), and the other was a short spindle shape one as shown by SM-AP5 (F).
Immunohistochemistry for keratin, duct epithelial marker (A-B) and S-100 protein, myoepithelial marker (C-D) in pleomorphic  adenoma cell systems: SM-AP1 (A, C), SM-AP4 (B, D) at day 6 after plating, indirect immunofluorescence, × 200 Figure 2
Immunohistochemistry for keratin, duct epithelial marker (A-B) and S-100 protein, myoepithelial marker (C-
D) in pleomorphic adenoma cell systems: SM-AP1 (A, C), SM-AP4 (B, D) at day 6 after plating, indirect 
immunofluorescence, × 200. All of the cell systems, SM-AP1 to SM-AP5, were equally immunopositive for keratin (A-B). 
SM-AP1, SM-AP2, and SM-AP3 cells were not definitely positive for S-100 protein (C), while SM-AP4 and SM-AP5 cells were 
strongly positive for S-100 protein (D).BMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
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Cytogenetic analysis of pleomorphic adenoma cell systems Figure 3
Cytogenetic analysis of pleomorphic adenoma cell systems. Panel A, chromosome numbers of pleomorphic adenoma 
cell systems: SM-AP1 (a), SM-AP2 (b), SM-AP3 (c), SM-AP4 (d), SM-AP5 (e), and those of cells in the primary culture (f) in his-
tograms. Panel B, G-banded karyotyping of SM-AP5. Chromosome numbers of the five cell systems varied between 64 and 
123, which were within tetraploid or pentaploid ranges, with a modal chromosome number of 108. Those of primary culture 
varied between 107 and 122 with a modal of 113.BMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
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Table 2: Chromosome counts and stemline karyotyps of pleomorphic adenoma cell systems.
stemline karyotypes
cell systems Cell numbers counted/karyotyped Chromosome numbers <ploidy> chromosomal abnomalities
SM-AP1 50/10 70–114 <5n> XX, -X[6], -X[3], add(X)(p11)[10], add(X)[5], 
add(X)(q11)[7], +1[7], add(1)(p11)x2[10], add(1)(q11)[10],
add(1)[9], -2[10], -2[10], +3[2], -3[5], 
der(3)add(3)(p11)del(3)(q2?)[10], der(3)add(3)del(3)[5],
der(3)add(3)del(3)[2], -4[9], add(4)(p11)[2], add(4)(q35)[10], 
add(4)[8], +5[2], add(5)(q11)[10], add(5)[6],
-6[9], -6[6], add(6)(q11)[8], -8[6], i(8)(q10)[10], i(8)[7], -9[3], 
der(9)t(9;13)(p13;q12)x2[10], -10[5],
i(10)(q10)[9], -11[5], add(11)(p15)[9], +12[8], 
add(12)(p11)x2[10], add(12)[9], -13[10], -13[10], -13[4],
add(13)(p11)[10], add(13)[4], -14[8], -14[3], 
add(14)(q32)[10], add(14)[9], +15[6], +16[2], -16[3],
add(16)(q2?2)[10], add(16)[3], -17[4], del(17)(p11)[8], -
18[9], add(18)(q11)[8], +19[8], +19[2], +20[8],
+20[8], +21[10], add(21)(p11)[8], add(21)(p11)[5], 
der(21)t(13;21)(q11;p11)[7], -22[10], -22[9], -22[6],
+mar1[9], +mar2[10], +mar2[5], +mar3[4], +mar5[2], 
+04mar.
SM-AP2 50/10 108–123 <5n> XX, -X[6], add(X)(p11)[10], add(X)[6], add(X)(q11)[7], 
add(X)[2], +1[8], +1[2], add(1)(p11)x2[10],
add(1)(p11)[2], add(1)(q11)[10], add(1)[7], -2[5], 
add(2)(p11)[7], idic(2)(q23)[7], -3[3],
der(3)add(3)(p11)del(3)(q2?)[10], der(3)add(3)del(3)[6], -
4[7], add(4)(q35)x2[10], +5[5], add(5)(q11)[9],
add(5)[4], +6[3], add(6)(q11)[9], del(6)(q25)[3], -8[9], 
i(8)(q10)x2[10], +9[2], -9[3],
der(9)t(9;13)(p13;q12)[10], der(9)t(9;13)[8], +10[7], +10[4], 
add(10)(p11)[4], i(10)(q10)[10], i(10)[7],
add(11)(p11)[9], add(11)(p15)[10], +12[7], 
add(12)(p11)x2[10], add(12)[8], -13[10], -13[10], -13[10],
-13[3], add(13)(p11)[10], add(13)[5], -14[7], 
add(14)(q32)x2[10], +15[6], -16[5], add(16)(q2?2)[8], -17[6],
del(17)(p11)[4], -18[8], add(18)(q11)[8], add(18)(q21)[2], 
add(18)(q23)[5], +19[7], +20[9], +20[3], -21[8],
add(21)(p11)[9], add(21)(p11)[10], add(21)(p11)[3], -22[10], 
-22[4],
+mar1[8], +mar2[10], +mar2[2], +mar3 × 2[10], +mar4[2], 
+07mar.
SM-AP3 50/10 64–109 <5n> XXX, -X[6], add(X)(p11) [10], add(X)(q11)[10], +1[8], 
add(1)(p11)x2[10], add(1)(q11)[10], add(1)[9],
-2[10], der(3)add(3)(p11)del(3)(q2?)x2[10], -4[7], 
add(4)(q35)x2[10], -5[6], add(5)(q11)[10], add(5)[5],
-6[9], -6[3], add(6)(q11)[7], -6[9], -6[3], add(6)(q11)[7], -
7[9], -7[3], der(7;10)(q10;q10)[7], i(7)(q10)[2],
-8[8], i(8)(q10)x2[10], -9[6], der(9)t(9;13)(p13;q12)x2[10], -
10[7], -10[3], del(10)(p12)[2], i(10)(q10)[2],
-11[6], add(11)(p11)[6], -12[5], add(12)(p11)[10], 
add(12)[3], -13[10], -13[10], -13[10], -13[9],
add(13)(p11)[9], -14[9], -14[5], add(14)(q32)[10], 
add(14)[8], +15[4], -15[5], -16[9], -16[3],
add(16)(q2?2)[8], -17[5], add(17)(p13)[8], del(17)(p11)[5], -
18[9], -18[3], add(18)(q11)[10], add(18)[4],
add(18)(q11)[2], add(18)(q21)[2], -19[6], +20[9], +20[8], 
+20[4], -21[9], -21[3], add(21)(p11)[10],
add(21)(p11)[4], der(21)t(13;21)(q11;p11)[10], -22[10], -
22[3],
+mar1[8], +mar2[10], +mar2[7], +mar3 [8], +mar4[3], 
+04mar.BMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
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SM-AP4 50/10 97–115 <5n> XX, -X[8], add(X)(p11)[10], add(X)(q11)[9], add(X)[2], 
+1[2], add(1)(p11)[9], add(1)[3],
add(1)(q11)x2[10], -2[9], -3[7], 
der(3)add(3)(p11)del(3)(q2?)x2[10], der(3)add(3)del(3)[3], -
4[10],
add(4)(q35)[10], add(4)[9], +5[2], -5[5], add(5)(q11)[10], 
add(5)[3], -6[7], add(6)(p11)[5],
add(6)(q11)[10], add(6)[5], +7[3], add(7)(q11)[4], -8[6], 
i(8)(q10)[10], i(8)[8], -9[5],
der(9)t(9;13)(p13;q12)[10], der(9)t(9;13)[7], -10[6], 
i(10)(q10)[9], i(10)[2], -11[7], add(12)(p11)x2[10],
-13[10], -13[10], -13[10],-13[4], add(13)(p11)[7], add(13)[2], 
add(13)(p11)[2], -14[9], add(14)(q32)[10],
add(14)[9], der(14)t(1;14)(q11;p11), -16[7], -16[3], 
add(16)(q2?2)[7], add(16)[2], -17[10], -17[8], -18[10],
-18[7], add(18)(q11)[9], add(18)[2], +19[5], +20[10], +20[9], 
+20[6], -21[10], -21[6], add(21)(p11)[9],
add(21)(p11)[2], der(21)t(13;21)(q11;p11)[9], -22[10], -
22[3],
+mar1[7], +mar2[8], +mar3[7], +mar4[3], +mar5[2], 
+03mar.
SM-AP5 50/10 109–122 <5n> XX, +add(X)(q11)[4], add(X)[9], add(X)(p11) [10], 
add(X)[9], +1[10], +1[3], add(1)(p11)[2],
add(1)(p11)x2[10], add(1)(q11)[10], add(1)[8], i(1)(q10)[3], -
2[10], -2[7], -3[4],
der(3)add(3)(p11)del(3)(q2?)[10], der(3)add(3)del(3)[3], 
der(3)add(3)(p11)del(3)(q2?)[2], -4[10],
add(4)(q35)x2[10], +5[9], add(5)(q11)x2[10], -6[8], 
add(6)(q11)[10], add(6)[2], -8[6], i(8)(q10)x2[10],
i(8)[3], +9[3], add(9)(p11)[5], der(9)t(9;13)(p13;q12)[10], 
der(9)t(9;13)[9], +10[10], i(10)(q10)x2[10],
-11[3], add(11)(p15)x2[10], add(11)[5], +12[5], 
add(12)(p11)x2[10], add(12)[5], -13[10], -13[10], -13[9],
add(13)(p11)x2[10], -14[10], add(14)(p11)[3], 
add(14)(p11)[4], add(14)(q32)[10], add(14)[9], +15[5],
+16[3], add(16)(q2?2)[10], add(16)[7], -17[8], -17[3], 
del(17)(p11)[3], -18[9],
-18[3], add(18)(q11)[6], add(18)(q23)[6], del(18)(q21)[2], 
+19[10], +19[3], +20[10], +20[10], +20[2],
-21[8], add(21)(p11)[10], add(21)(p11)[2], -22[9], -22[7], -
22[3],
+mar1[9], +mar2[10], +mar2[6], +mar3[8], +mar3[6], 
+mar5[2], +06mar.
Primary 20/20 107–122 <5n> XX, -X, -X, -X, add(1)(p11), add(1)(q?12) x2, -2, -3, -3, 
add(4)(q31.3)x2, +5,
der(5)add(5)(p15.1)add(5)(q22)x2, -6, add(6)(q21)x2, 
+add(7)(q11.2)x2, i(8)(q10)x2,
-9, add(9)(p11), der(9)t(9;13)(p13;q12)x2, +10, 
add(10)(p11.1), i(10)(q10)x2, +11,
add(11)(p11.2), add(11)(p15), +12, +12, add(12)(p11.2)x4, -
13, -13, -13, -13, -14,
add(14)(q?24)x2, +15, add(16)(q?12.1), -17, ? 
add(17)(p11.2)x2, -18, -18, +19, +20,
-21, -21, -21, -22, +mar1 × 2, +mar2 × 2, +mar3 × 2, +mar4 
× 2, +mar5 × 2 [cp20]
Table 2: Chromosome counts and stemline karyotyps of pleomorphic adenoma cell systems. (Continued)BMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
Page 11 of 17
(page number not for citation purposes)
102~114<5n>, XX in SM-AP1; 113~121<5n>, XX in SM-
AP2; 98~108<5n>, XXX in SM-AP3; 97~115<5n>, XX, in
SM-AP4; 114~121<5n>, XX in SM-AP5. Figure 3B repre-
sents the SM-AP5 stemline karyotype. All of the cell sys-
tems had numerous chromosomal abnormalities, such as
deletion, translocation and marker chromosomes as
shown in Table 2. Among them, additional materials of
unknown origin such as add(X)(p11),
der(3)add(3)(p11)der(3)(q2?), add(4)(q35) and translo-
cations such as der(9)t(9;13)(p13;q12), add(12)(p11),
and add(14)(q32) were shared by all of them. Since the
der(9)t(9;13)(p13;q12) was the only abnormality in
which the origin of translocated chromosomes was evi-
dent, this translocation was further analyzed for its break
points by the FISH technique as described below. Chro-
mosome 17, where the p53  gene is located at p13,
decreased in number in all of the cell systems. In addition,
del(17)(p11) was shared by four cell systems except for
SM-AP4. SM-AP3 cells had add(17)(p13), which might
have affected the p53 gene locus.
Primary cultured cells shared the same translocations as
those of the established SM-AP cell systems, such as
der(9)t(9;13)(p13;q12) and add(12)(p11) (Table 2).
Peripheral blood lymphocytes from the patient had nor-
mal chromosome numbers and karyotype (not shown).
Screening of chromosomal break points for translocation 
t(9;13)(p13;q12)
To restrict the break points for the translocation
t(9;13)(p13;q12), which was shared by all five cell sys-
tems, FISH analyses for chromosome 9p13 and 13q12
regions were performed. By using the primer sets listed in
Table 1, three clones for chromosome 9 (p13) and four
clones for chromosome 13 (q12) were isolated by PCR to
map their chromosomal locations. Clear single or paired
FISH signals were demonstrated by the BAC clones,
1537E12 (Figure 4A-b) and 1405F1 (Figure 4A-c), which
are located in chromosome 9p13.2 and 9p13.1, respec-
tively (Figure 4A-a). BAC clones by 1325C2 in chromo-
some 13q12.2 (Figure 4B-a) were localized on
chromosomes with translocation t(9;13)(p13;q12) (Fig-
ure 4B-c). FISH signals for 1213F4, which is located in
chromosome 13q13.1, were not found on any chromo-
somes (Figure 4B-b). Thus, break points for the transloca-
tion, t(9;13)(p13;q12), were thought to be located in
restricted regions of 9p13.3 and 13q12.3.
P53 gene analysis
PCR amplicons for exons 5, 6 and 7 of the p53 genes from
the primary cultured cells as well as from all of the SM-AP
cell systems were sequenced, and deletion of the last base
G of codon #249 (AGG to AG_) of exon 7 was found in all
of them including the primary culture (Figure 5). Owing
to this point mutation, a nonsense polypeptide should
have been generated on and after codon #249, resulting in
non-functional p53 gene products. No other mutations
were found in exons 5 and 6.
Xenografts of SM-AP cells in nude mice
Five cell systems, SM-AP1 to SM-AP5, successfully formed
subcutaneous tumors in nude mice after 5 to 19 weeks of
injections (Figure 6A, Table 3). The tumors which had
grown to 10 to 15 mm in diameter were harvested for his-
topathological examinations (Figure 6B). Histologically,
transplanted tumors showed rather expansive growths
mostly limited to the range of the dermis to the subcutis
or to only the surface part of the muscle layer, although
they had no definite fibrous capsules. Tumor cell nests
varied in size, and some of them contained keratinization
centers, irrespective of transplanted tumors. Hence, squa-
mous cell carcinomas were basically diagnosed for all of
the tumors formed by the five cell systems. However, their
keratinization seemed to occur suddenly without gradual
differentiation tendencies in the tumor cell nests, which
had no basal cell alignment at the periphery of the tumor
cell nests (Figure 6C), which were usually not seen in
squamous cell carcinomas of the oral mucosal origin. In
the transplanted tumors of SM-AP1 to SM-AP3, which had
been regarded as duct-epithelial by immunofluorescence
in vitro, there were tendencies to form mimics of ductal
structures (Figure 6D, arrow). Those of SM-AP1 and SM-
AP2 contained tumor cells with plasmacytoid appear-
ances (Figure 6E). In those of SM-AP4 and SM-AP5, which
had rather myoepithelial natures in vitro, tumor cell nests
were sheet-like with some tendencies toward keratiniza-
tion, and they showed ground glass-like cytoplasm (Fig-
ure 6F). Mitotic figures were observed in each tumor but
more frequently in SM-AP4 and SM-AP5 (Figure 6G,
arrows), suggestive of their malignant natures. Hyaline
stromal spaces without definite vascular channels and
lymphocytic infiltration were formed between tumor cell
nests in every tumor, which were also unusual in oral
squamous cell carcinomas (Figure 6H). Immunohisto-
chemically, the hyaline stroma was strongly positive for
perlecan (Figure 6I) as well as for fibronectin (Figure 6J).
Although there was no area with a typical histology of
benign pleomorphic adenoma in the transplanted
tumors, the presence of ductal mimics, plasmacytoid cells,
ground-glass appearance of tumor cell cytoplasm and pre-
dominant hyaline stroma mentioned above might indi-
cate their pleomorphic adenoma origin. However, there
were no foci of salivary duct carcinoma, which is common
in carcinoma ex pleomorphic adenoma. Immunohisto-
chemically, the transplanted tumors of SM-AP1 to SM-
AP5 were stained positive for keratin. SM-AP1, SM-AP2,
and SM-AP3 cells were not positive for S-100 protein,
while SM-AP4 and SM-AP5 cells were strongly positive for
other myoepithelial markers, such as CK14 and calponin,
in addition to S-100 protein. All five transplanted cell sys-BMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
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Fluorescence in-situ hybridization (FISH) for screening of break points for the translocation, t(9;13)(p13;q12) in SM-AP5, by  using BAC clones Figure 4
Fluorescence in-situ hybridization (FISH) for screening of break points for the translocation, t(9;13)(p13;q12) 
in SM-AP5, by using BAC clones. Panel A, mapping of BAC clones of chromosome 9 (a) and FISH for 9p13.2 by BAC 
1537E12 (b) and for 9p13.1 by BAC 1405F1 (c). Panel B, mapping of BAC clones of chromosome 13 (a) and FISH for 13q12.2 
by BAC 1325C2 (b) and for 13q13.1 by BAC 1213F4 (c). × 800. Signals of BAC clones, 1537E12 and1405F1 for chromosome 
9p13.2 (A-b) and 9p13.1(A-c), 1325C2 for chromosome 13q12.2 (B-c) were detected as clear single and/or paired fluorescence 
dots on the translocation t(9;13)(p13;q12) chromosome, while no signal for BAC clone 1213F4 for chromosome 13q13.1 was 
seen (B-b).BMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
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tems showed no P53 protein immunopositivities (not
shown).
Discussion
In the present study, we were successful in establishing the
five cell systems, SM-AP1 to SM-AP5, from a benign
parotid gland pleomorphic adenoma. We previously sug-
gested a potential of atypical tumor cells scattered in
benign pleomorphic adenomas to develop into focal car-
cinomas and then into tangible forms of carcinoma ex
pleomorphic adenoma [3], although it had been ques-
tionable whether the presence of these atypical cells
within pleomorphic adenoma could be recognized as
sources for the secondary onset of malignancy [4-6].
There have been three trials in the literature to establish
cell lines/systems from pleomorphic adenomas in which
only their malignant or transformed natures of the cells
were reported with no definite histological characteriza-
tion as squamous cell carcinoma [19-21], and two were
from carcinoma ex pleomorphic adenomas [13,22], in
addition to those from mere primary cultures [7-9,23-27].
In terms of cell shapes in culture, the cell system by Bull-
erdiek et al. was spindle [22], and CaPA-4 cells by Fujioka
et al. [13] were squamous epithelial. In our immunohisto-
chemical study, polygonal-shaped SM-AP1 to SM-AP3
were shown to be duct-epithelial, while spindle-shaped
SM-AP4 and SM-AP5 were myoepithelial. In addition,
their xenografts presented some ductal (SM-AP1-SM-AP3)
or myoepithelial (SM-AP1 and SM-AP2 by plasmacytoid
appearances) differentiation.
Interestingly, the two cell lines from carcinoma ex pleo-
morphic adenoma [13,22] were demonstrated to have
characteristics of squamous cell carcinoma when they
were transplanted into nude mice, as was also observed in
the present study. Although our cell systems lost benign
features of pleomorphic and had definite tendencies
towards keratinization in xenografts, their histology was
not always typical as seen in oral mucosal squamous cell
carcinomas ones in terms of their cytoplasm and stroma.
SM-AP cells had their characteristic cytoplasm with
ground-glass appearances, and their hyaline or myxoid
stromata were rich in perlecan and fibronectin and poorly
vascularized. These features indicated that they were of
pleomorphic adenoma origin. It took longer periods for
them to form transplanted tumors, and they had no ulcer-
ation or metastasis, indicating that they were not so
aggressive.
The five pleomorphic adenoma cell systems cloned in the
present study showed aneuploid karyotypes and various
kinds of chromosomal abnormalities, of which the trans-
location, der(9)t(9;13)(p13;q12), was stably shared by all
of the clones. As a chromosome 9-related alteration, a
reciprocal translocation t(9:12)(p13-21;q13-15) was
found in benign pleomorphic adenomas by Mark et al.
[24]. In the present study, we were able to restrict the
break points of t(9;13)(p13;q12) within 9p13.3 and
13q12.3 in these cell systems. The result indicates that
genes located in the distal region of 9p13.3 and the prox-
imal region of 13q12.3 ares missing. The distal region of
9p13.3 is known to contain interferon  cluster (IFNA), a
tumor suppressor gene (9p22) [31], methylthioadenosine
phosphorylase (MTAP) (9p21) [32], and p16 (9p21) [33],
and the break point at 13q12.3 contains IFN-inducible
gene, namely the IFI-56K [34]. A role of p16 gene in the
secondary onset of malignancy in pleomorphic adenomas
has been hypothesized by Suzuki & Fujioka [33]. Since
9p13 rearrangements seem to be generated at the stage of
pleomorphic adenoma, pleomorphic adenoma could be
regarded as substantially malignant in nature even if it has
a benign histological feature. The deletions of 9p22 con-
taining IFNA and 9p21 containing MTAP and p16 genes
and 9p allelic losses were also observed in oral squamous
cell carcinoma [33,35-37].
None of the five pleomorphic adenoma cell systems in the
present study showed any of these translocations involv-
ing 8q12, where PLAG1, one of the most extensively
investigated genes in pleomorphic adenomas, is located.
Astrom et al. [8] claimed that the 8q12 abnormalities are
not a requirement for the enhanced expression of PLGA1
in pleomorphic adenoma by using primary cultures of
both pleomorphic adenoma and carcinoma ex pleomor-
phic adenoma with or without 8q12 abnormalities.
Abnormalities such as t(6,8)(p21-23;q12) [23],
Mutational analysis of the p53 gene in genomic DNA from  pleomorphic adenoma cells in the primary culture as well as  from the five SM-AP cell systems Figure 5
Mutational analysis of the p53 gene in genomic DNA 
from pleomorphic adenoma cells in the primary cul-
ture as well as from the five SM-AP cell systems. PCR-
amplicons for exons 5, 6 and 7 of the p53 gene were directly 
sequenced, and the deletion of the last base G of codon 249 
(AGG to AG-) in exon 7 was shared by all of the cell systems 
and the primary culture.BMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
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Figure 6 (see legend on next page)BMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
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t(9;12)(p13-21;q13-15) [24], del(5)(q22-23;q32-33),
t(10;12)(p15;q14-15) [38], and t(12;?)(q13-15;?) [22]
found in our cell systems constitute a new finding in ple-
omorphic adenoma.
Loss of heterozygosity (LOH) has been demonstrated, by
using surgical materials, at chromosome arms 8q (52%),
12q (28%), and 17p (14%) in benign pleomorphic ade-
nomas and in adenoma components of carcinoma ex ple-
omorphic adenoma, whereas the ratios of LOH in 8q, 12q
and 17p loci were enhanced up to 69%, 50%, and 69%,
respectively, in carcinoma ex pleomorphic adenoma [39].
In our present result, pleomorphic adenoma cell systems
tended to decrease numbers of chromosome 17 and
abnormalities of add(17)(p11) and add(17)(p13). These
chromosomal abnormalities may affect transcription of
the p53 gene, which is located in 17p13.
The present result demonstrating that p53 gene products
were not detectable immunohistochemically in the five
cell systems both in culture and xenografts are consistent
with the data from CaPA-4 cells [13]. In the previous
reports, immunohistochemical expressions of P53 pro-
tein were not always obtained in tumor cells or in the
cases examined (3% to 41% for pleomorphic adenoma
cases and 41% to 75% for carcinoma ex pleomorphic ade-
noma cases) [10,11,15,16]. There may be two interpreta-
tions for the non-immunopositivity for p53 gene products
in our cell systems: one is that the protein expression lev-
els were lower than the sensitivity of the method, and
another is that mutated gene products could not be recog-
nized by the antibody, Bp53-11. The latter seems to be
more likely in our case because the point mutation in
codon #249 in exon 7, which was shared by all of the cell
systems, should have generated a nonsense gene product,
which could not be recognized by the antibody whose
antigenic site is the transcriptional transactivation
domain within the NH2-terminal region [40]. Since we
confirmed that this point mutation at codon #249 even in
cells in the primary culture might have existed before
cloning transformed SM-AP cells, this suggests that this
mutation plays a role in the tumorigenesis of benign ple-
omorphic adenoma as well as in its malignant transfor-
mation. Interestingly, the G to A transitional point
mutation at the next codon #248 found in CaPA-4 cells
was also found in the surgical tissue samples from the ade-
noma portion as well as from the carcinoma portion of
their original carcinoma ex pleomorphic adenoma [13].
Thus, the mutations of the p53 gene should be considered
to be an early event in the malignant transformation.
Conclusion
The present data suggest that pleomorphic adenoma con-
tains cells with genetic alterations even when its histology
is benign and that carcinoma cells may develop from
some of the population of benign forms. Whether the
atypical cells within benign pleomorphic adenoma [3]
can be the direct source for malignant transformation is
Transplanted tumors of SM-AP cell systems in nude mice Figure 6 (see previous page)
Transplanted tumors of SM-AP cell systems in nude mice. Macroscopic view of a tumor mass by SM-AP5 in lateral 
back in a nude mouse (A); cut surface view of a subcutaneous tumor by SM-AP1 (B); histopathology of transplanted tumors by 
SM-AP4 (C), SM-AP1 (D, E), SM-AP5 (F, G), and SM-AP3 (H). HE stain, C, × 100; D-G, × 320; H, × 240; immunoperoxidase 
stains of SM-AP3 transplants for perlecan (I) and fibronectin (J), × 200, hematoxylin counterstain. SM-AP cells formed subcuta-
neous tumors measuring about 10 mm in diameter in nude mice within one to four months (A). The tumors were rather lim-
ited to the dermis expanding into the superficial part of the muscle layer but had no capsular structure (B). Histopathologically, 
the tumors were basically squamous cell carcinomas with definite tendencies towards keratinization with invasive natures, 
although there was no basal cell alignment along the periphery of the tumor cell nests (C). Around the tumor cell nests, 
myxoid stroma was induced. SM-AP1 to SM-AP3 cells formed mimics of ductal structures (D), and at the same time, SM-AP1 
and SM-AP2 showed plasmacytoid appearances (E). SM-AP4 and SM-AP5 cells formed less differentiated carcinomas composed 
of tumor cells with ground-glass-like cytoplasm (F). Irrespective of tumors, mitotic figures were frequently observed (G), and 
the stromata were wide, hyaline, and poor in vascularity and lymphocytic infiltration (H). The hyaline stroma was immunoposi-
tive for perlecan (I) and fibronectin (J).
Table 3: Tumorgenicity of pleomorphic adenoma cell systems.
cell systems Number of mice with tumors (n = 2) Mean time of tumor appearance (weeks)
SM-AP1 2 7.5
SM-AP2 1 9
SM-AP3 1 19
SM-AP4 1 5
SM-AP5 2 9BMC Cancer 2009, 9:247 http://www.biomedcentral.com/1471-2407/9/247
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hard to say. Since all of the xenografted tumors in nude
mice were histologically squamous cell carcinomas, the
present establishment of pleomorphic adenoma-derived
squamous cell carcinoma cells can be regarded as an in-
vitro demonstration of secondary development of malig-
nancy from a benign adenoma. This process may corre-
spond to the clinical form of carcinoma ex pleomorphic
adenoma. However, it may be possible at least to specu-
late that under the circumstances, in which atypical cells
are generated, pleomorphic adenoma cells attain some
background for the secondary onset of malignancy, which
may be generated from the combination of the p53 gene
mutation and other chimera genes resulting from the spe-
cific translocations involving der(9)t(9; 13)(p13.3;
q12.3) and other chromosome abnormalities.
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